{"id":"W3128747576","doi":"10.1016/s0140-6736(21)00125-2","title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":297,"is_retracted":false,"has_abstract":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma","keywords":"Medicine; Ustekinumab; Psoriasis; Placebo; Psoriasis Area and Severity Index; Clinical endpoint; Internal medicine; Adverse effect; Clinical trial; Randomization; Dosing; Body surface area; Plaque psoriasis; Randomized controlled trial; Dermatology; Adalimumab; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002433921,0.001609662,0.003694901,0.0003705326,0.0005140209,0.001546656,0.001022619,0.002282132,0.005286223],"category_scores_gemma":[0.001828376,0.0007826139,0.002782482,0.0003962918,0.001190746,0.001170015,0.0004625295,0.003982853,0.00106378],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008122312,"about_ca_system_score_gemma":0.0008739895,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001052627,"about_ca_topic_score_gemma":0.002066184,"domain_scores_codex":[0.9992483,0.000384847,0.00003705128,0.0001371631,0.00006260343,0.0001298781],"domain_scores_gemma":[0.9990425,0.0003017905,0.0002199849,0.00008188622,0.00005062455,0.0003032273],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9814186,0.002024279,0.0003452073,0.0005476886,0.0009608032,0.0000321364,0.00004632838,0.0002166068,0.002137932,0.00009988111,0.00083252,0.01133798],"study_design_scores_gemma":[0.96816,0.02863584,0.001529967,0.00003285395,0.0004671025,0.00004814255,0.00001892464,0.0002260492,0.0002379318,0.0001550416,0.0004746165,0.00001346925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9752388,0.01529922,0.000946724,0.001371861,0.0006287604,0.001665546,0.001798235,0.0002288776,0.002822025],"genre_scores_gemma":[0.9847798,0.005066891,0.001460534,0.001614912,0.0005235078,0.001617721,0.001440423,0.00004443391,0.003451851],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005286223,"threshold_uncertainty_score":0.01768416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09074387936814433,"score_gpt":0.3299520541258157,"score_spread":0.2392081747576714,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}